T1	Participants 229 237	patients
T2	Participants 276 315	Sixty-eight evaluable patients with MDS
T3	Participants 772 792	two treatment groups
T4	Participants 833 840	patient
T5	Participants 853 865	13-CRA group
T6	Participants 874 908	patients (6%) in the placebo group
T7	Participants 952 960	patients
T8	Participants 964 975	both groups
T9	Participants 1086 1094	patients
T10	Participants 1290 1301	in patients
